Research & Academia

Executive Summary Pfizer has introduced a new platform called USTAT (Unified Sequential Template Amplification and Transcription). The platform uses Rolling Circle Amplification (RCA) to establish an mRNA manufacturing process that does not rely on traditional plasmid DNA. The time from DNA template generation to mRNA production can potentially be reduced to approximately two days. RNA quality approaches that of conventional plasmid DNA-based manufacturing, although challenge

Introduction: For the First Time, Treatment Is About More Than Controlling Blood Sugar For more than a century, the treatment of Type 1 Diabetes (T1D) has been relatively straightforward. If the body cannot produce insulin, we replace insulin. This approach has saved millions of lives since the discovery of insulin in 1921. However, if we look deeper, one important fact becomes apparent: We have never truly addressed the underlying disease. The problem is not simply a lack of

Introduction: Many People Think mRNA Has Already Succeeded — But It’s Just Getting Started Ask most people what mRNA is, and you’ll probably hear answers like: COVID-19 vaccines Moderna Pfizer The breakthrough technology of the pandemic And they wouldn’t be wrong. COVID-19 vaccines represent one of the most successful commercial applications of mRNA technology in history. However, if you ask scientists working in RNA therapeutics, gene therapy, or drug delivery, you may hear

Introduction: The Next Bottleneck in mRNA Therapeutics May Not Be RNA—It May Be the LNP Since the successful launch of COVID-19 mRNA vaccines, mRNA technology has rapidly expanded beyond infectious diseases into areas such as cancer immunotherapy, gene editing, protein replacement therapy, and regenerative medicine. Many scientists believe the next decade will be the golden age of RNA therapeutics. However, anyone who has worked in mRNA drug development quickly realizes a fun

Introduction How Amino Acids Enhance LNP mRNA Delivery: A New Direction for mRNA Therapeutics Over the past few years, lipid nanoparticles (LNPs) have become the cornerstone of modern mRNA therapeutics. From COVID-19 mRNA vaccines to cancer immunotherapy, rare disease treatment, and gene editing, LNPs are now one of the most important delivery platforms for nucleic acid medicines. But anyone who has worked in drug delivery knows a frustrating reality: An LNP system that perfo

Introduction: Treatment Is No Longer Just About Controlling Blood Glucose For decades, the treatment of Type 1 Diabetes (T1D) has been relatively straightforward. If the body cannot produce insulin, we replace it. This approach works. It allows patients to manage the disease and maintain quality of life. But if you look one layer deeper, a fundamental limitation becomes clear: We have never truly changed the disease itself. The problem is not just a lack of insulin.It is that

Introduction: This Is Not a Sudden Disease Most people think of Type 1 Diabetes (T1D) as something that suddenly appears —one day you’re diagnosed, and from that point on, you depend on insulin. But from a biological perspective, T1D is not an abrupt event.It is a long, gradual process that can unfold over years, even decades. At the center of this process is the progressive breakdown of the Type 1 Diabetes autoimmune mechanism. The real question is not about blood glucose.It

Introduction: The Problem Was Never Just Blood Glucose If you’ve ever worked closely with Type 1 Diabetes (T1D), one realization comes quickly: “Dysregulated blood glucose” is just the final outcome. The real issue lies deeper — a systemic failure: The immune system begins to attack the body itself. This is why, despite over a century of insulin therapy, we’ve been able to manage T1D —but never truly solve it. 1. What is Type 1 Diabetes? (Type 1 Diabetes Overview) At its core

Executive Summary B cell protein factory represents a new paradigm for biologics delivery Through HSPC gene editing , B cells can be engineered to continuously secrete antibodies or therapeutic proteins The system is boostable, long-term, and capable of multi-protein output This signals a shift in cell therapy—from “killing cells” to “producing proteins” Companies like Be Biopharma and Immusoft are already moving in this direction Introduction: Are We Redefining Biologics?

Introduction: Are We Finally Beginning to “Understand” Biological Systems? In the past, the biotech industry rarely truly understood the systems it worked with. What we mostly did was: Run experiments Observe outcomes Adjust accordingly This approach works—but at its core, it is still trial-and-error driven science . The emergence of Digital Twin in Biotech represents a fundamental shift: We are starting to understand systems before running experiments. This is not just ab

Executive Summary Antibody drug conjugates (ADCs) have become one of the most important innovations in oncology and the broader biotech industry in recent years. Over the past decade, antibody drug conjugates have evolved from early-stage research tools into an integrated system spanning science, clinical development, manufacturing, and market strategy. Understanding ADCs solely from the perspective of molecular design or clinical efficacy is no longer sufficient. Antibody d

Introduction: Are We Missing the Most Important Piece? Over the past few years, mRNA therapeutics has rapidly expanded—from vaccines to cancer immunotherapy, gene editing, and protein replacement. But if you’ve actually worked in this space, you’ve probably had this intuition: Often, it’s not that your design isn’t good enough—it’s that delivery just doesn’t work. So we optimize: Codon usage Nucleoside modifications Cap and poly(A) tail LNP formulations All of these matter. B

Executive Summary Antibody–drug conjugates (ADCs) have rapidly evolved from an innovative therapeutic modality into one of the most strategically important areas in the biotech industry. In recent years, the ADC market has undergone significant changes: A surge in licensing deals and M&A activity Increasing investment from large pharmaceutical companies in ADC pipelines Growing focus among biotech startups on ADC platform technologies These trends indicate that: The ADC mark

Executive Summary Antibody–drug conjugates (ADCs) hold tremendous promise in both scientific innovation and clinical applications, but they also present significant challenges in manufacturing. Compared to traditional biologics or small-molecule drugs, ADC production involves: biologics (antibodies) highly potent small molecules (payloads) complex conjugation chemistry As a result, ADC manufacturing and CMC (Chemistry, Manufacturing, and Controls) often become critical bottl

Introduction: The Next Step of CAR-T Is Not “Better” — It’s “Simpler” Over the past decade, CAR-T therapy has proven that we can treat cancer with engineered immune cells. But the real bottleneck is never efficiency, but rather: Too high cost The manufacturing process is too slow Patients can't wait The essence of traditional CAR-T is actually "personalized cell manufacturing". Now, a more fundamental question has arisen: What if CAR-T didn't need to be manufactured at all? T

Executive Summary- ADC clinical development Antibody–drug conjugates (ADCs) have achieved major advances at the scientific and engineering levels, yet clinical success remains highly variable. Many ADCs: show strong performance in preclinical models demonstrate early responses in Phase I trials ultimately fail in Phase II or Phase III studies This indicates that the challenge is not solely molecular design, but rather: ADC clinical development strategy Successful ADC programs

In Vivo CAR-T Autoimmune Therapy: Reprogramming the Immune System In Situ Introduction CAR-T therapy has already transformed hematologic oncology. Yet its expansion into autoimmune disease has been limited by cost, manufacturing complexity, and scalability challenges. A new paradigm is emerging: in vivo CAR-T autoimmune therapy . Instead of extracting T cells, engineering them ex vivo, and reinfusing them weeks later, in vivo approaches program immune cells directly inside th

Executive Summary Over the past decade, antibody–drug conjugates (ADCs) have become one of the most important therapeutic platforms in oncology drug development. Several ADCs have achieved major clinical success, particularly in breast cancer, hematologic malignancies, and emerging solid tumor indications. However, early generations of ADCs were still constrained by important limitations, including: reliance on a single payload mechanism dependence on a single tumor antigen

Introduction Following the success of COVID-19 vaccines, mRNA technology has rapidly emerged as one of the most important platforms in modern biotechnology . By enabling human cells to temporarily produce therapeutic proteins, mRNA therapeutics are being explored across a wide range of medical applications, including: Vaccines Cancer immunotherapy Protein replacement therapies Gene editing (CRISPR delivery) However, mRNA molecules are inherently fragile. Without protection,

Executive Summary Over the past decade, antibody–drug conjugates (ADCs) have emerged as one of the most promising platforms in oncology drug development. However, even clinically successful ADCs rarely maintain long-term tumor control when used as single agents. The reason is not simply insufficient drug potency. Tumors possess remarkable adaptive capacity and can gradually evade ADC-mediated cytotoxicity through mechanisms such as antigen downregulation, altered internaliza